Quantcast

Industry news that matters to you.  Learn more

Archives for September 2014

Definiens to Host the First International Symposium for Tissue Phenomics This Fall

Definiens, the global leader in Tissue Phenomics™ for oncology diagnostics, recently announced that registration is now open for the company’s inaugural conference, The International Symposium for Tissue Phenomics. Alongside genomics, Tissue Phenomics is a key driver in the growth of personalized medicine, and the symposium brings together thought leaders from around the globe on companion diagnostics, immunotherapy, and tissue-based patient stratification for personalized medicine. The Symposium will begin with a keynote lecture from Nobel Laureate, Gerd Binnig, Ph.D., discussing his approach to uncovering novel diagnostics through using big data in tissue.

Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study

A novel biomarker for rheumatoid arthritis (RA) has significant potential to help physicians better identify early-stage disease, when treatment can often arrest further disease progression and disability, according to a new study in The Journal of Rheumatology.

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy

KineMed, Inc. recently announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications.  Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions.  ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.

Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics

Genomic Health, Inc. (Nasdaq: GHDX) recently announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment.